{"id":"W2122026430","doi":"10.1093/infdis/jis750","title":"Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study","year":2012,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":312,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Dolutegravir; Raltegravir; Regimen; Cohort; Medicine; Viral load; Integrase inhibitor; Elvitegravir; Dosing; Internal medicine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003685675,0.000183063,0.000447441,0.0001635039,0.0001215068,0.000008659238,0.00007043425,0.00003023449,0.00001230123],"category_scores_gemma":[0.0002014902,0.00007988141,0.0000978079,0.000502673,0.0001311719,0.0001188373,0.00003043026,0.0001278351,0.000001049317],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001861304,"about_ca_system_score_gemma":0.0002488032,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002540904,"about_ca_topic_score_gemma":0.0002686665,"domain_scores_codex":[0.998581,0.0002551683,0.0005458521,0.00009476567,0.0003312851,0.0001919283],"domain_scores_gemma":[0.9986477,0.0003311473,0.0005011992,0.0002403621,0.0001573617,0.0001221536],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01060298,0.004349699,0.9724762,0.00002683454,0.0004579825,0.00001867083,0.01019668,0.00006053783,0.0006181862,0.00001615312,0.00004247184,0.001133601],"study_design_scores_gemma":[0.01306034,0.003165537,0.9779921,0.000310328,0.000922617,0.0001371213,0.002121887,0.000003247846,0.001941012,0.0000119547,0.0002472982,0.00008652069],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978058,0.0009133892,0.000006181,0.0001794711,0.0001364493,0.0005713886,0.000008806245,0.000009546426,0.0003689176],"genre_scores_gemma":[0.9992251,0.00038781,0.00002149092,0.00001307799,0.00007515361,0.000005289412,0.000002400392,0.00001360261,0.0002560411],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008074795,"threshold_uncertainty_score":0.325747,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01656090380541293,"score_gpt":0.27322790795775,"score_spread":0.2566670041523371,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}